Kenvue Inc. (NYSE:KVUE) continues to attract investment interest with the likes of
Private Advisor Group LLC and
Longbow Finance SA increasing their stock positions.
Piper Sandler and
William Blair have issued positive and market perform rating respectively. With additional interest from investing bodies including
Dynasty Wealth Management LLC,
Handelsbanken Fonder AB,
Action Management One Co. Ltd, and
Bleakley Financial Group among others, Kenvue's investment portfolio seems robust. However, not all are buying; institutions like
Bank of New York Mellon Corp and
Los Angeles Capital Management LLC have lowered their holdings. Courting controversy, Kenvue is under
class action lawsuit for a stock drop affecting investors. Analysts estimate a decline in earnings and 2025 profit below estimates. Meanwhile, activist investor
Starboard Value has entered a board nomination battle. Major products in Kenvue's portfolio like
Tylenol and
Neutrogena show potential despite current sales slump, with exciting future plans indicated by the CEO. Finally,
merger and
dividend discussions continue, with stock targeted by activist hedge funds, and
takeover speculation driving a gain.
Kenvue KVUE News Analytics from Mon, 23 Sep 2024 07:00:00 GMT to Sat, 01 Mar 2025 10:45:05 GMT -
Rating -6
- Innovation 0
- Information 2
- Rumor 4
